info@mdrevenuegroup.com9:00 AM - 5:00 PM | Mon - Fri
MD Revenue Group provides specialized, high-performance revenue cycle management for independent hematology and oncology practices, multi-physician oncology groups, and specialized infusion centers. We eliminate "Capital Erosion" by mastering the complex 2026 shifts in high-cost biologic authorizations, J-code unit-level precision, and the mandatory waste reporting (JZ/JW) requirements that now define oncological margin protection. Our Medical Billing Services are engineered to transform your oncology practice from a high-liability drug purchaser into a proactive capital recovery engine.
Claim Free Oncology AuditFor an independent hematologist-oncologist, the choice to outsource RCM isn't about giving up control—it's about gaining technical leverage against aggressive payers who want to default your medication reimbursement to "Invoice Cost." Our Medical Billing Services provide the administrative backbone required to allow your oncologists to focus on patient outcomes rather than financial liability.
As you add new infusion protocols, specialized molecular diagnostics, or specialized radiation oncology equipment, your billing scales instantly without the need for additional Credentialing staff or office space.
By catching technical and mathematical errors (like Payer Enrollment gaps or unlinked pharmacy contracts) *before* submission, we dramatically accelerate your cash flow for clinical growth.
We build "Audit-Armor" into the foundation of your oncology practice. Our experts ensure that every infusion log, every drug waste record, and every molecular authorization is "Ready for Scrutiny" before it ever leaves your office.
Oncology is a specialty defined by extreme financial risk and the administrative burden of managing medications that can cost upwards of $20,000 per dose. In 2026, the cost of cancer care medications and the administrative friction of authorization have reached a point where a single "Unit-Level" or "Modifier" error can cause a practice to lose its entire procedural margin.
A primary source of revenue erosion for oncology practices is the failure to perfectly synchronize the drug units administered with the units allowed by the payer’s specific medical policy. In 2026, if the HCPCS units don't match the "Volume-to-Dose" calculation in the clinical chart, the claim is auto-denied or downcoded. We implement Revenue Integrity protocols to ensure every milligram of high-cost chemotherapy is captured.
For 2026, CMS and major commercial payers have made drug waste reporting (Modifier -JW for discarded amounts, Modifier -JZ for zero waste) mandatory for all single-dose vial medications. Most oncology groups lose 8-10% of their drug revenue simply by failing to document and bill the "Discarded Units" correctly. MDRG’s Revenue Cycle Management experts specialize in technical waste reconciliation to avoid these systemic losses.
Payers are increasingly denying biomarker and genetic testing claims (81200–81599) due to "Lack of Specificity" in the treatment plan. In 2026, payers require the testing to be explicitly linked to a "Next-Line Therapy" decision. Our team manages the "Authorization Path" to ensure these high-cost diagnostics are paid on the first pass.
Topical authority in oncology RCM involves mastering the 96400-series CPT codes and the nuances of high-complexity drug delivery systems. Our oncology-certified coders ensure every Revenue Cycle Management submission is optimized for technical success.
Push vs. Infusion vs. Extended time
Exact HCPCS units & waste capture
Bundling & technical component split
Managing the 60-min clinical threshold
2026 mandatory waste reporting
2026 mandatory zero-waste reporting
Defending evaluation parity
In 2026, oncology billing is a battle of "Clinical Calculation." Payers are no longer just looking for coding errors; they are using AI-driven auditing to challenge the *dosage* and *waste* of high-cost biologics. We defend your revenue against these three high-frequency rejection types:
Payer bots often deny entire medication claims if they detect a "Vial Mismatch"—where a single-use vial was billed but no waste (-JW) or zero-waste (-JZ) modifier was applied. In 2026, this is the #1 reason for oncology payment delay.
Many payers have updated their 2026 audit triggers for genetic testing. If the chart doesn't explicitly state how the test result will change the chemotherapy protocol, the testing is denied as "Investigational."
For newer specialized immunotherapy mappings or CAR-T cell transitions, payers often trigger "Experimental" denials even for FDA-cleared protocols.
In 2026, the key to oncology revenue is the "Technical Intensity Narrative." We help your providers implement "Audit-Armor" charting strategies that signal authority to payer algorithms. This includes using "Trigger Phrases" for testing necessity and automating the capture of specialized infusion technical data.
We help you structure your infusion records so that the "Technical Necessity" of a separately identifiable encounter is undeniable to even the most aggressive automated payer bots.
We teach your team how to describe patient presentation in a way that reflects the true "Diagnostic Intensity" of the work, reducing the risk of automated downcoding.
MDRG acts as your practice’s "Oncology RCM Command Center." We focus entirely on Revenue Cycle Management efficiency so you can focus on clinical stabilize and patient care.
We synchronize with your EHR (OncoEMR, Aria, Mosaiq, etc.) to establish a clean, high-speed data bridge.
Every oncology claim is scrubbed for 2026 CPT/Diagnosis parity before it hits the clearinghouse. We look for "Waste Red-Flags" that AI-payers use to auto-delete high-value biologic lines.
We don't accept "No." We challenge every technical drug and diagnostic denial with clinical precision, leveraging our oncology-certified coders to file high-level appeals for your most complex cases.
Track your net collections, "Per-Visit Acuity Yield," and payer performance points with total transparency via our secure client portal.
To defend your oncology revenue in 2026, your infusion and treatment records must be bulletproof. We provide our oncology clients with a rigorous documentation checklist to ensure compliance:
In a technical audit for a 10-physician independent oncology group in the Southeast, MDRG identified a $282,000 annual revenue leakage in their drug-waste (JW) and biomarker testing billing. The group was failing to correctly document "Milligram-Level Waste" and was omitting the mandatory JZ modifier for zero-waste vials.
By implementing Revenue Cycle Management best practices—including real-time "Waste-Capture Training" for their clinical staff—MDRG was able to: * **Recover $188,000 in uncaptured drug waste and testing revenue** within the first 6 months. * **Reduce their "Waste-Mismatch" Denial Rate** by 72% using specialized technical narratives. * **Accelerate Cash Flow** by reducing their average days in A/R from 45 days to 23 days.
This oncology group now operates with "Audit-Armor" protection, knowing that every high-value patient hour is protected from automated payer clawbacks.
In the high-intensity environment of 2026, your oncology practice deserves a revenue cycle that is as precise as your clinical care. Don't let your "Clinical Capital" be eroded by primitive billing and administrative friction.
Direct PDF download. We respect medical practice privacy.
Get a free audit of your billing. If we don't find money you're leaving on the table, you don't pay a dime.
